×
Taysha Gene Therapies Share Holder Equity 2020-2024 | TSHA
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Taysha Gene Therapies share holder equity from 2020 to 2024. Share holder equity can be defined as the sum of preferred and common equity items
View More
Taysha Gene Therapies Share Holder Equity 2020-2024 | TSHA
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Taysha Gene Therapies share holder equity from 2020 to 2024. Share holder equity can be defined as the sum of preferred and common equity items
Related Stocks
Company Name
Market
Cap
Teva Pharmaceutical Industries (TEVA)
$19.4B
Dr Reddy's Laboratories (RDY)
$12.6B
BridgeBio Pharma (BBIO)
$5.1B
Bausch Health Cos (BHC)
$3.4B
Amphastar Pharmaceuticals (AMPH)
$2.4B
Supernus Pharmaceuticals (SUPN)
$2B
Personalis (PSNL)
$241M
Assembly Biosciences (ASMB)
$106M
Sol-Gel Technologies (SLGL)
$16M
Evoke Pharma (EVOK)
$5M
Teligent (TLGT)
$0M